Screener
Bio-Techne TECH Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056302
| Line item | Nine Months Ended / March 31, 2026 | Nine Months Ended / March 31, 2025 |
|---|---|---|
| Net cash provided by (used in) investing activities | (11,133) | (35,589) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Cash dividends | (37,432) | (38,004) |
| Proceeds from stock option exercises | 58,193 | 45,513 |
| Repurchases of common stock | (24) | (175,674) |
| Borrowings under line-of-credit agreement | — | 38,000 |
| Repayments of long-term debt | (146,000) | (27,000) |
| Taxes paid on RSUs and net share settlements | (10,643) | (6,288) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Bio-Techne's stock issuance proceeds?
- Bio-Techne (TECH) reported stock issuance proceeds of $29.96M in Q1 2026.
- How has Bio-Techne's stock issuance proceeds changed year-over-year?
- Bio-Techne's stock issuance proceeds increased by 101.4% year-over-year, from $14.87M to $29.96M.
- What is the long-term trend for Bio-Techne's stock issuance proceeds?
- Over 3 years (2022 to 2025), Bio-Techne's stock issuance proceeds has grown at a -12.5% compound annual growth rate (CAGR), from $77.16M to $51.74M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Bio-Techne's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude